A cancer diagnostics company, Precipio (NASDAQ: PRPO) surges 13% minimum on more than 7 million shares after signing an agreement with ADS Biotec to distribute IV-Cell cytogenetics cell culturing media.
PRPO soared to $6.91 from $1.23 on 97.20 million shares on July 30th. Before that day the stock was flat as a floor in a typical apartment. Because of launching an antibody test for COVID-19, the penny stock popped drastically within a day.
Diversifying the revenue sources make PRPO survive in an uncertain healthcare field that requires a lot of funds to develop highly effective products and solutions to fight cancer and other serious diseases. Soon its EPS may add some beneficial points to attract long-staying stock traders.
Finance and Entertainment Reporter
Richard is a bottle of wine – the older the sweeter. He has already found the sweetest hobby in writing entertainment and finance news for Own Snap. Readers get the updated posts regularly from him searching for real-time news.